Edison Pharmaceuticals Nabs $20M To Treat Mitochondrial Disease
Mountain View-based Edison Pharmaceuticals, a biopharmaceuticals firm developing treatments for mitochondrial diseases, has raised $20M in a Series F funding. The round was led by Mitsui & Co. Edison said the funding will go to advance clinical development of its EPI-743 compound. Mitsui gains a seat on the board with the funding.
posted on Tuesday, November 27, 2012 (Link to more information)
Related companies:
Edison Agrosciences, Inc.
Related stories:
> Edison Pharmaceuticals Lands Series E
> Arriva Pharmaceuticals Adds $6M
> Edison Software Acquires Business From Return Path
> Verge Genomics Gets $4M
> Virobay Gets $8M In Additional Series B
silicontap.com Home